NAIROBI, 5 November 2026 — Kenya is preparing to introduce artesunate-pyronaridine (ASPY) as an additional first-line malaria treatment after a research study identified molecular markers associated with partial artemisinin resistance in parasite samples collected across several counties.
The planned treatment change was reported by Nation Media Group on 5 November, citing the Ministry of Health’s National Malaria Control Programme. The report says the first batch of ASPY is expected in November, with an initial rollout in Baringo, Kakamega, Siaya and Busia counties from January 2027. The programme is expected to use ASPY alongside artemether-lumefantrine (AL), rather than immediately replacing AL nationwide.
The policy discussion follows a peer-reviewed study published in Malaria Journal on 5 October 2026. Researchers analysed 675 Plasmodium falciparum samples collected between 2018 and 2024 from eight hospitals across four of Kenya’s five malaria transmission zones. The study identified four mutations recognised by WHO as validated markers of partial artemisinin resistance. It reported that the A675V marker was concentrated in Baringo, where it was detected in 12 of 71 samples tested from the county.
The authors described the Baringo finding as the first molecular evidence consistent with suspected partial artemisinin resistance in the county. The result is a warning signal for surveillance and treatment policy, but it does not mean that all malaria infections in Kenya are resistant to current medicines or that treatment failure has been established across the country. Molecular markers need to be interpreted alongside therapeutic efficacy studies and clinical outcomes.
Why it matters
Artemisinin-based combination therapies are central to malaria treatment in many African countries. Partial resistance can slow parasite clearance and threaten the effectiveness of treatment if resistant parasites become more common or spread. Preserving effective medicines is therefore essential, particularly in high-transmission areas where repeated infections and treatment demand place sustained pressure on health services.
Kenya’s study is important because it provides geographically specific evidence from multiple transmission settings, including areas where malaria is seasonal. Baringo’s signal warrants closer monitoring, but the findings should not be overstated: the study examined genetic markers in sampled parasites and does not by itself measure the clinical effectiveness of every treatment regimen used in the country.
What happens next?
According to the 5 November media report, Kenya expects the first ASPY supplies during November and plans an initial multiple-first-line-therapy rollout in four counties from January 2027. The Ministry’s reported plan is to use more than one recommended first-line combination and rotate treatment choices over time to reduce selection pressure on a single regimen. The detailed implementation schedule, product quantities, procurement arrangements and monitoring indicators should be confirmed through formal Ministry of Health guidance.
The study authors recommend enhanced molecular surveillance and therapeutic efficacy monitoring. These are necessary to determine whether the identified markers are associated with slower parasite clearance or reduced cure rates under routine conditions. Health authorities will also need to monitor medicine safety, adherence, stock availability and the quality of malaria diagnosis.
What it means for Kenya and the region
For Kenya, the findings support a more geographically responsive malaria strategy. Counties with different transmission patterns may need tailored surveillance and treatment implementation, while national guidance must ensure that clinicians understand which patients should receive each regimen. The media report notes that AL is expected to remain an option for groups for whom ASPY may not be suitable, including pregnant women and very small infants; clinicians should follow the final national treatment guidelines rather than make regimen changes independently.
The wider region is also watching artemisinin resistance. WHO has documented partial resistance markers in several African countries, making cross-border molecular surveillance and sharing of treatment-efficacy data increasingly important. Parasites do not respect national borders, and delayed detection can make it harder to contain the spread of resistant strains.
What solutions are available?
Key measures include multiple first-line treatment strategies where supported by national policy, routine therapeutic efficacy studies, molecular surveillance, reliable diagnostic testing, quality-assured medicines, adherence counselling and strong pharmacovigilance. Vector control, insecticide-treated nets, indoor residual spraying where appropriate, and prompt access to diagnosis remain essential; changing treatment policy does not replace malaria prevention.
Who is offering them?
The Ministry of Health’s National Malaria Control Programme is responsible for national policy and implementation. KEMRI and collaborating research institutions generate surveillance evidence. County health departments and healthcare workers will be central to rollout, training and monitoring. The 5 November report says the new supply is being arranged under the Kenya–United States government health partnership; the exact procurement and financing terms should be confirmed from the responsible agencies.
Health Signal Africa will continue tracking: the official rollout circular, arrival and distribution of ASPY supplies, the counties covered, treatment guidance for special populations, and new therapeutic efficacy and molecular surveillance results.
Sources and further reading
- Malaria Journal / PubMed — Spatial surveillance of Plasmodium falciparum Kelch 13 mutations and suspected partial artemisinin resistance in Baringo, Kenya (5 October 2026)
- Nation — New malaria drug to be unveiled to stay ahead of resistance (5 November 2026)
- WHO Global Malaria Programme — Malaria treatment and drug-resistance guidance




Discussion
A thoroughly well-researched and insightful analysis on “kenya malaria treatment artemisinin resistanc…”. Appreciate the dedication to detailed analysis here. Keep up the great work!